The EHA Guidelines Workshop, a meaningful and successful first Series!
November 2020 – April 2021
In the past six months, hematologists, clinicians, transfusion medicine specialists, oncologists, special nurses and researchers gathered virtually for the first EHA Guidelines Workshop series. The 1,5 hour workshops were dedicated to Guidelines produced or endorsed by EHA. Through Guidelines Overview presentations and patients cases the lead authors and other experts disseminated good practices and knowledge for diagnosis and treatment of hematologic diseases.
The series of online workshops dedicated to EHA guidelines were supported with an unrestricted grant by Janssen. In the period from November 2020 to April 2021 each workshop covered different hematologic diseases in both benign and malignant settings. The free workshops were well attended by delegates from over 112 countries. Attendees had the opportunity to actively participate by submitting their questions live during the Q&A panel discussions and instantly test their knowledge through the interactive polling questions. Although the meeting was fully virtual, the platform complimented all the features of a physical meeting. Attendees had the chance to connect and interact with their peers by scheduling 1-on-1 meetings. In addition all live sessions were available on-demand in the platform until April 30.
The EHA Guidelines Workshop series focused on the topics Pregnancy in Rare Inherited Anemias, Lymphoma, CMML, CLL, Multiple Myeloma and Bleeding Disorders. Below you will find an short overview of each Workshop.
- EHA Guidelines Workshop Pregnancy in Rare Inherited Anemias
Chairs: A Iolascon (Italy) & A Taher (Lebanon)
Date: November 25, 2020
Prior to the publication of this EHA Recommendations for Pregnancy in Rare Inherited Anemias, there were no clear-cut guidelines outlining the pathophysiological trends and management options unique to this special population. In this 1st workshop, experts discussed the impact of rare anemias, such as sickle-cell disease, thalassemia, and congenital dyserythropoietic anemia type 2, on maternal and fetal outcomes. The aim of the workshop was to increase the knowledge of standardized therapeutic interventions for the management of pregnancy in rare inherited anemias
1. EHA Endorsement of ESMO Clinical Practice Guidelines on Hodgkin Lymphoma
Chairs: I Aurer (HR) & M Federico (IT)
Date: December 15, 2020
In the 2nd workshop, the focus was on the epidemiology, the patient allocation, as well as the diagnosis of early, intermediate, and advanced Hodgkin lymphoma. The aim of the workshop was to increase the knowledge of diagnosis, treatment and follow-up for Hodgkin lymphoma (HL) based on ESMO Guidelines (endorsed by EHA).
2. EHA Guidelines Workshop Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults
Chairs: P Fenaux (FR) & L Malcovati (IT)
Date: January 14, 2021
This 3rd workshop dove into the diagnosis and classification of CMML, prognostic factors and treatment strategies, including non-transplant strategies and targeted drug therapies. The aim of the workshop was to increase the knowledge of Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults.
3. EHA Endorsement of ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up of Chronic Lymphocytic Leukemia
Chairs: B Eichhorst (DE) & P Ghia (IT)
Date: February 23, 2021
In the 4th workshop, the focus was on treatment therapies for people with TP53 mutation and IgHV mutations, as well as therapies for relapsed patients, such as chemoimmunotherapy and targeted agents. The aim of the workshop was to increase the knowledge & insights on diagnosis classification, prognosis and treatment decisions and follow-up in patients with Chronic Lymphocytic Leukemia (CLL).
4. Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Chairs: MA Dimopoulos (GR) & P Sonneveld (NL)
Date: March 16, 2021
The 5th workshop presented the first ever joint EHA-ESMO guideline on Multiple Myeloma, with a focus on front-line therapies and treatments options for relapsed/refractory patients. The aim of the workshop was to knowledge & insights on diagnosis classification, prognosis and treatment decisions and follow-up in patients with multiple myeloma.
5. Fundamentals for a Systematic Approach to Mild and Moderate Inherited Bleeding Disorders: An EHA Consensus Report
Chairs: R Abdul-Kadir (UK), I Pabinger (AT) & F Rodeghiero (IT)
Date: April 20, 2021
In this last workshop, panelists defined mild and moderate inherited bleeding disorders, reviewed clinical criteria, and discussed a comprehensive patient-centered diagnostic approach. The aim of the workshop was to increase the knowledge on diagnosis and management of patients with mild or moderate bleeding disorders.
EHA would like to thank all the Guidelines Authors, the Clinical Case presenters, the workshop Sponsor, ESMO, and the attendees for their contribution in making the first EHA Guidelines Workshop series a great success. We look forward to meeting all of you during EHA2021 and for the second EHA Guidelines Workshops series, which will start in Autumn 2021.
If you would like to learn more about the EHA Guidelines click here.